Targeting PIEZO1 ‐ TMEM16F Coupling to Mitigate Sickle Cell Disease Complications
American Journal of Hematology · 2025-12 · 100 (12) · 2261-2275
DOI: 10.1002/ajh.70086 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 08.10.2025. Verfasst von Pengfei Liang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Anoctamins, Phospholipid Transfer Proteins, Ion Channels. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, American Society of Hematology Graduate Hematology Award to Yuichun Wan Scholar Award to Pengfei Liang, American Society of Hematology.
Abstract (Originalsprache)
A deeper understanding of sickle cell disease (SCD) pathophysiology is critical for identifying novel therapeutic targets. A hallmark of SCD is abnormal phosphatidylserine (PS) exposure on sickle red blood cells (RBCs), which contributes to anemia, thrombosis, and vaso‐occlusive crises (VOC). However, the mechanisms underlying this excessive PS exposure remain unclear. Here, we identify TMEM16F, a Ca 2+ ‐activated lipid scramblase, as a key mediator of PS exposure downstream of Ca 2+ influx through the mechanosensitive channel PIEZO1 in sickle RBCs. Electrophysiology, imaging, and flow cytometry reveal that deoxygenation‐induced sickling activates PIEZO1, triggering Ca 2+ entry, TMEM16F activation, and PS exposure. This cascade promotes PS + microparticle release, thrombin generation, and RBC adhesion to endothelial cells. Notably, partial PIEZO1 inhibition with benzbromarone, an anti‐gout drug, suppresses these effects. Our findings define a previously unrecognized mechanotransduction pathway in sickle RBCs and propose a unique therapeutic strategy to mitigate hypercoagulability and vaso‐occlusion associated with SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
- Department of Neurobiology, Duke University School of Medicine, Durham, North Carolina, USA.
ORCID-Profile: Sanjay Khandelwal, Huanghe Yang
Förderung
- NIGMS NIH HHS
- American Society of Hematology Graduate Hematology Award to Yuichun Wan Scholar Award to Pengfei Liang
- American Society of Hematology
- National Institute of General Medical Sciences
Zitieren
APA
Liang, P., Wan, Y. S., Shan, K. Z., Chou, R., Zhang, Y., Delahunty, M., Khandelwal, S., Francis, S. J., Arepally, G. M., Telen, M. J., & Yang, H. (2025). Targeting PIEZO1 ‐ TMEM16F Coupling to Mitigate Sickle Cell Disease Complications. American Journal of Hematology, 100(12), 2261-2275. https://doi.org/10.1002/ajh.70086
Vancouver
Liang P, Wan YS, Shan KZ, Chou R, Zhang Y, Delahunty M, et al. Targeting PIEZO1 ‐ TMEM16F Coupling to Mitigate Sickle Cell Disease Complications. American Journal of Hematology. 2025;100(12):2261-2275. doi:10.1002/ajh.70086
BibTeX
@article{Liang2025,
author = {Liang, Pengfei and Wan, Yui-Chun S and Shan, Ke Z and Chou, Ryan and Zhang, Yang and Delahunty, Martha and Khandelwal, Sanjay and Francis, Samuel J and Arepally, Gowthami M and Telen, Marilyn J and Yang, Huanghe},
title = {Targeting PIEZO1 ‐ TMEM16F Coupling to Mitigate Sickle Cell Disease Complications},
journal = {American Journal of Hematology},
year = {2025},
volume = {100},
number = {12},
pages = {2261--2275},
doi = {10.1002/ajh.70086}
}
EUVIMED